Acuitive Technologies earns FDA clearance for new bone void filler

Acuitive Technologies earned FDA clearance for the Citrepore bioactive bone filler, the company said Nov. 12.

Advertisement

Four things to know:

1. Citrate is designed for orthopedic surgery and is made with the company’s patented Citregen biomaterial.

2. The implant is reabsorbed and replaced by the patient’s bone and lets Citrepore guide healing metabolically.

3. Citrepore has more than 80% porosity and is osteoconductive and bioactive.

4. The implant is available in a variety of performed shapes and sizes and can be cut or morselized.

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Biologics

  • Atreon Orthopedics and RenovoDerm have merged, according to a May 19 news release. Together the companies will leverage a comprehensive…

  • Miach Orthopaedics named Jamal Rushdy as its new CEO, according to a May 11 news release. Mr. Rushdy replaces Patrick…

  • Xtant Medical launched the Trivium Shaped bone graft, part of the Trivium bone graft portfolio, according to a May 6…

Advertisement

Comments are closed.